Orexo AB (ST:ORX) has successfully navigated a challenging Q1,16 with the loss of CVS Health Corp (NYSE:CVS) exclusive status at restricted plans, emerging with positive operating cash flow due to working capital and a focus on cost control (total spend down 17% vs Q4). In the near term, management priorities are Zubsolv revenue growth, balanced with appropriate sales investment to target profitability. Investment will increase as Zubsolv’s market access and reimbursement position improves, and federal legislation is passed significantly expanding the available market. Global expansion with a potential new ex-US partner for Zubsolv represents further upside; a deal is targeted for Q216, with European filing planned in H216.
Zubsolv: Balanced investment to capture growth
Increased investment in promotional activities depends on opportunities to gain market share: market access improvements and legislative change nationally. Increasing the number of patients with unrestricted access to Zubsolv and further growing the profitable cash and commercial segments are a key focus. Federally, proposed changes to government policy would expand access to opioid dependence treatment through both current and new prescribers.
To read the entire report Please click on the pdf File Below